Kiora Pharmaceuticals appoints David Hollander, MD, MBA to its Board of Directors

KIORA PHARMACEUTICALS INC

Appointment effective December 13, 2021; press release issued December 15, 2021.
Hollander is Chief R&D Officer at Aerie Pharmaceuticals, with extensive ophthalmic industry experience.
He fills a vacancy created by board resignations in August 2021.
Will serve as Class III director until 2024 Annual Meeting of Stockholders.
Board determined he is independent under Nasdaq Capital Market rules.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David Hollander

Director

KPRX · KIORA PHARMACEUTICALS INC

Effective: 2021-12-13
Filed: December 15, 2021, 6:59 PM ET

On December 13, 2021, the Board of Directors (the “Board”) of Kiora Pharmaceuticals, Inc. (the “Company”) appointed David Hollander, MD, MBA as a member of the Board to fill a vacancy created by the previously disclosed resignations of two directors from the Board in August 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Hollander was appointed as Director at KIORA PHARMACEUTICALS INC.

Action: appointed
Role: Director

Exact text from the filing

On December 13, 2021, the Board of Directors (the “Board”) of Kiora Pharmaceuticals, Inc. (the “Company”) appointed David Hollander, MD, MBA as a member of the Board to fill a vacancy created by the previously disclosed resignations of two directors from the Board in August 2021.

View on SEC.gov

KIORA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-21-149776

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.